A Phase 2 Study of Foscenvivint in Liver Cirrhosis Patients Caused by HIV/HCV Co-infection With Hemophilia

Study acronym: OP-724-H202
StatusRecruiting
PhasePhase 2
Started

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Track this trial
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Enrollment increased: 4 → 7 participants
    • Study sites: 3 to 4
    • Start date changed from estimate of Sep 1, 2026 to Oct 1, 2026
    • Eligibility criteria expanded, about 13 words
  2. Recruitment opened
    • Site details revised at 3 of 3 sites
    v3
  3. Study title revisedv2
  4. Study First Submitted
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This is a phase 2 study to evaluate the efficacy and safety of foscenvivint in patients with liver cirrhosis resulting from HIV/HCV co-infection in the setting of hemophilia.
Trial Details
NCT Number NCT07681089
Lead Sponsor Kiminori Kimura, MD
Collaborators: Japan Agency for Medical Research and Development, Ohara Pharmaceutical Co., Ltd.
Conditions
(from sponsor)		 Liver Cirrhosis
Related terms Hemophilia A, Liver Cirrhosis
Enrollment 7 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov